EUVIMEDEUVIMED entdecken
Crossref

Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma

Taku Kikuchi, Nobuhiro Tsukada, Kodai Kunisada, Moe Nomura-Yogo, Yuki Oda, Kota Sato, Tomomi Takei, Mizuki Ogura, Yu Abe, Kenshi Suzuki, Tadao Ishida

Acta Haematologica · 2024

DOI: 10.1159/000539066 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Acta Haematologica, 2024. Verfasst von Taku Kikuchi und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Monoclonal, Humanized, Cytomegalovirus, Cytomegalovirus Infections. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 14 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Some treatments are associated with cytomegalovirus (CMV) reactivation (CMVRA) in patients with multiple myeloma (MM). However, no reports exist on the association between elotuzumab and CMVRA. Therefore, we assessed the incidence of CMVRA in patients with MM who received elotuzumab therapy.

Methods

The medical records of 85 patients who underwent elotuzumab therapy were included in the retrospective analysis for CMV positivity.

Results

Thirty patients were tested for CMV antigenemia during elotuzumab therapy, and 16 were positive for CMV antigenemia; the cumulative incidence rate of CMVRA 6 months after elotuzumab initiation was 18.4%. The history of allogeneic stem cell transplantation (allo-HSCT) was significantly more common in the CMVRA group (31.2%) than that of the group without CMVRA (8.7%). However, even among patients who did not undergo allo-HSCT, the cumulative incidence rate of CMVRA at 6 months was 15.1%. During CMVRA, the symptoms included fever in 8 cases, while retinitis was observed in 1 case. Five patients required antiviral therapy and CMV antigenemia resolved in all but 1 case.

Conclusion

Although the patient population was heterogeneous, CMVRA cannot be underestimated during elotuzumab therapy, and evaluation of CMVRA, especially in symptomatic cases, is clinically important.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaAntibodies, Monoclonal, HumanizedCytomegalovirusCytomegalovirus InfectionsVirus ActivationAntineoplastic Agents, ImmunologicalHumansMaleFemaleMiddle AgedAgedRetrospective StudiesAdultHematopoietic Stem Cell Transplantation

Stichwörter der Autor:innen

Antiviral agentsCytomegalovirusElotuzumabReactivation

Substanzen

Antibodies, Monoclonal, HumanizedelotuzumabAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.

Zitieren

APA

Kikuchi, T., Tsukada, N., Kunisada, K., Nomura-Yogo, M., Oda, Y., Sato, K., Takei, T., Ogura, M., Abe, Y., Suzuki, K., & Ishida, T. (2024). Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma. Acta Haematologica. https://doi.org/10.1159/000539066

Vancouver

Kikuchi T, Tsukada N, Kunisada K, Nomura-Yogo M, Oda Y, Sato K, et al. Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma. Acta Haematologica. 2024. doi:10.1159/000539066

BibTeX
@article{Kikuchi2024,
  author = {Kikuchi, Taku and Tsukada, Nobuhiro and Kunisada, Kodai and Nomura-Yogo, Moe and Oda, Yuki and Sato, Kota and Takei, Tomomi and Ogura, Mizuki and Abe, Yu and Suzuki, Kenshi and Ishida, Tadao},
  title = {Cytomegalovirus Reactivation during Elotuzumab Therapy in Patients with Multiple Myeloma},
  journal = {Acta Haematologica},
  year = {2024},
  doi = {10.1159/000539066}
}
Kostenlos starten →